An Exploratory Clinical Study of CDK4/6i Dalpiciclib Combined With AI Neoadjuvant Therapy for Stage II-III HR+/HER2- Breast Cancer

NCT06613373 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Dalpiciclib

Sponsor

Jiangsu Famous Medical Technology Co., Ltd.